Want to see DOCS full AI Analyst Report?
DOCS Stock Chart & Stats
$24.71
-$0.33(-0.59%)
At close: 4:00 PM EST
$24.71
-$0.33(-0.59%)
Day’s Range― - ―
52-Week Range$17.15 - $76.51
Previous CloseN/A
Volume296.07K
Average Volume (3M)4.92M
Market Cap
$3.95B
Enterprise Value$3.62B
Total Cash (Recent Filing)$748.60M
Total Debt (Recent Filing)$10.19M
Price to Earnings (P/E)20.8
Beta1.45
Next Earnings
Aug 11, 2026EPS Estimate
0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.04
Shares Outstanding131,975,430
10 Day Avg. Volume3,145,102
30 Day Avg. Volume4,924,310
Financial Highlights & Ratios
PEG Ratio-1.89
Price to Book (P/B)4.58
Price to Sales (P/S)6.76
P/FCF Ratio13.72
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue5.61
Enterprise Value/Gross Profit6.29
Enterprise Value/Ebitda13.59
Forecast
1Y Price Target
$24.82Price Target Upside0.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)1.43
Revenue Forecast (FY)$670.51M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageExtremely low leverage and a sizable equity/cash base provide durable financial flexibility. This reduces default risk, enables sustained R&D/AI investment, underpins share repurchases and M&A optionality, and shields operations from cyclical ad-market weakness over the medium term.
Strong Cash Generation & Free Cash FlowHigh and growing free cash flow with operating cash well above net income demonstrates strong cash conversion. Persistent FCF funds reinvestment, buybacks, and higher short-term compute/R&D spend without needing external financing, supporting durable capital allocation flexibility.
High Margins, Recurring Revenue & Customer RetentionExceptionally high gross margins and robust adjusted EBITDA reflect a scalable, software-led model. Strong net revenue retention and concentrated enterprise customers create durable recurring revenue, pricing power, and high lifetime value that support long‑term profitability even amid elevated investment.
Bears Say
Near‑term Revenue DecelerationA meaningful slowdown in top‑line growth reduces the runway for operating leverage and increases reliance on cost control or non‑organic moves to meet profit targets. If sustained, slower revenue expansion could limit returns on AI investments and constrain long‑term TAM capture.
AI Investment Costs And Delayed MonetizationHeavy near‑term investment in AI compute, R&D and marketing plus regulatory friction delays monetization. This combination can compress margins for multiple quarters, push out payback timelines on product investments, and increase execution risk around commercializing AI features.
Revenue Concentration Among Large CustomersHigh revenue concentration increases exposure to a relatively small set of customers. Loss, downsizing or repricing by a few large clients would materially impact results, reducing diversification benefits and making long‑term growth more sensitive to enterprise sales cycles and contract renewals.
Doximity News
DOCS FAQ
What was Doximity, Inc.’s price range in the past 12 months?
Doximity, Inc. lowest stock price was $17.15 and its highest was $76.51 in the past 12 months.
What is Doximity, Inc.’s market cap?
Doximity, Inc.’s market cap is $3.95B.
When is Doximity, Inc.’s upcoming earnings report date?
Doximity, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 40 days.
How were Doximity, Inc.’s earnings last quarter?
Doximity, Inc. released its earnings results on May 13, 2026. The company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.283 by -$0.023.
Is Doximity, Inc. overvalued?
According to Wall Street analysts Doximity, Inc.’s price is currently Undervalued.
Does Doximity, Inc. pay dividends?
Doximity, Inc. does not currently pay dividends.
What is Doximity, Inc.’s EPS estimate?
Doximity, Inc.’s EPS estimate is 0.3.
How many shares outstanding does Doximity, Inc. have?
Doximity, Inc. has 131,975,430 shares outstanding.
What happened to Doximity, Inc.’s price movement after its last earnings report?
Doximity, Inc. reported an EPS of $0.26 in its last earnings report, missing expectations of $0.283. Following the earnings report the stock price went down -23.001%.
Which hedge fund is a major shareholder of Doximity, Inc.?
Currently, no hedge funds are holding shares in DOCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Doximity Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.82 (0.46% Upside)
$24.82 (0.46% Upside)
Blogger Sentiment
Bullish
DOCS Sentiment 86%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 112.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.18%
12-Months-Change
Fundamentals
Return on Equity
19.36%
Trailing 12-Months
Asset Growth
-11.00%
Trailing 12-Months
Company Description
Doximity, Inc.
Doximity, Inc. provides a digital platform, hosted in the cloud, specifically designed for healthcare practitioners throughout the United States. This platform delivers a suite of specialized tools, empowering its members to connect with peers, streamline patient treatment, conduct remote consultations, access current medical information and research, and advance their professional careers. Its primary clientele consists of pharmaceutical companies and healthcare organizations. Established in 2010, the entity initially operated as 3MD Communications, Inc. before rebranding to Doximity, Inc. in June of that year. The company's corporate headquarters are situated in San Francisco, California.
DOCS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong financial health (record free cash flow, solid full-year revenue growth, high adjusted EBITDA and cash balance), robust engagement and rapid AI adoption across physicians and health systems, and meaningful early commercial traction for AI products. Offsetting these positives are near-term margin pressure from rising AI compute and investments, slower revenue guidance (~4% FY27 growth at midpoint), delayed AI monetization due to regulatory reviews, and softer bookings/visibility driven by policy and macro uncertainty. Management frames the year as an "AI investment year"—accepting short-term margin impact to capture a larger long-term TAM.View all DOCS earnings summariesDOCS Revenue Breakdown
93.00% Subscription
7.00% Other
DOCS Stock 12 Month Forecast
Average Price Target
$24.82
▲(0.46% Upside)
Technical Analysis
Omnicell
―
Evolent Health
―
Teladoc
―
Definitive Healthcare Corp
―
Tempus AI, Inc. Class A
―
Ownership Overview
2.98% Insiders
25.81% Mutual Funds
24.94% Other Institutional Investors
25.02% Public Companies and
Individual Investors